Say your pulmonologist recently confirmed pulmonary hypertension, and you are already on an approved medicine. Online, someone mentions inhaled VIP or aviptadil as a “natural vessel opener” for high pressure in the lungs. Is there a human study behind that pitch?
Yes, but it is modest. In 2008, researchers in Munich had 20 people inhale aviptadil once during right-heart catheterization. They saw a small, short-lived drop in lung-vessel resistance in some patients, not a lasting therapy result.
Why VIP was tried in the cath lab
Vasoactive intestinal peptide can widen blood vessels and is low in some people with idiopathic pulmonary arterial hypertension. Leuchte and colleagues tested whether inhaling aviptadil, a form of VIP, would change pressures and blood gases right away. The group included nine people with PAH, eight with pulmonary hypertension tied to lung disease, and three with chronic thromboembolic disease.
Each person inhaled aviptadil once while catheters measured heart and lung pressures. The aerosol caused a small and temporary selective pulmonary vasodilation, a better stroke volume, and a higher mixed venous oxygen saturation. Six of the 20 had a pulmonary vascular resistance drop of more than 20 percent. In people who also had significant lung disease, oxygenation tended to improve. The authors called the vasodilating effect modest and short-lived and reported no side effects in that single-dose session.
How this differs from other VIP files
Everyday Brief has already covered VIP in two other settings: hospital COVID-era aviptadil programs, and an open inhaled-VIP study in sarcoidosis that tracked immune signals in lung washings. Those are different diseases and different study designs. The 2008 catheterization study is a one-time physiology test, not proof that a research-catalog VIP vial treats pulmonary hypertension at home.
The National Heart, Lung, and Blood Institute describes pulmonary hypertension as high blood pressure in the lungs that can strain the right side of the heart, and it points people to specialist care and approved therapies. MedlinePlus likewise stresses diagnosis and supervised treatment. A catalog peptide is not an approved PAH inhaler.
Questions for the next specialty visit
Ask which approved pulmonary hypertension medicines you already qualify for, and whether any registered trial of inhaled VIP is still enrolling. If a wellness page cites “VIP for lung pressure,” ask whether it means this single-dose cath-lab signal or something else. A short, temporary monitor change in 20 people is a research clue, not a reason to replace medicines your specialist prescribed.
Not medical advice.
Sources
- Leuchte HH et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J, 2008 (PubMed)
- NHLBI: Pulmonary hypertension
- MedlinePlus: Pulmonary hypertension
Related reading
- VIP/aviptadil hospital COVID trials vs research listings
- Inhaled VIP in sarcoidosis: what one open study measured
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-13 PT. Not medical advice.